CIGC Physicians Provide Tailored Hormone
Speak at length to your GYN specialist about your long-term goals and how hormone replacement therapy can play a role in managing menopause symptoms, especially in the transition and early stages.
Hormone replacement therapy (HRT) is a medical treatment for women that are menopausal, perimenopausal, or postmenopausal that can help relieve symptoms caused by the decrease in estrogen and progesterone. Estrogen is the female hormone that helps minimize or eliminate menopausal symptoms. Typically, menopause occurs in up to 83 percent of women between the ages of 50 and 52, but can occur earlier or later in times1. Hormone replacement therapy can help alleviate symptoms, such as sweating and hot flashes, by balancing estrogen and progesterone in the body.
If you are confused about whether HRT is right for you, you are not alone. The medical community has flip-flopped on this issue over the last few decades and the misinterpretation of data in general media articles creates a feeling of uneasiness for many patients when considering hormone therapy.
Hormone replacement therapy is not one size fits all. The type of therapy, and when it is administered, matters greatly.
Hormone Replacement Therapy Types
Hormone therapy can be given in two ways1:
Low-dose Vaginal Estrogen Therapy
These products are used to treat vaginal symptoms but do not help with other menopausal symptoms, such as hot flashes, mood changes, or bone loss. They can be taken as a vaginal cream, ring, or vaginal tablet.
Systemic Hormone Therapy
This is what is often referred to as “hormone replacement therapy,” or “HRT.” There are various forms, including oral pills, transdermal patches, or transdermal creams, sprays, or gels. It is important to note that there are two types of systemic hormone therapies: estrogen-only therapy (ET), and combination estrogen and progesterone therapy (EPT). Use of either single-agent estrogen therapy or combined therapy depends on the age of the patient and whether or not the uterus is in place (below).
Benefits of HRT?
Hormone replacement therapy, either estrogen-only or combined with progesterone, has been shown in multiple studies to be the most effective treatment available for menopausal symptoms. Estrogen is the most effective treatment available for relief of menopausal symptoms, most importantly hot flashes. In women with a uterus, a combination of both estrogen and progesterone may be a more appropriate treatment, since it is more likely to decrease the risk of endometrial hyperplasia and cancer. Estrogen-only HRT should only be used in menopause if a woman has had a hysterectomy. If symptoms are bothersome, there are several options available.
Some women may derive secondary benefits from taking estrogen-only therapy, including preventing chronic diseases such as coronary heart disease, dementia, or osteoporosis. However, it is not recommended as a first-line medication to address these conditions.
Age is the most important factor when prescribing HRT. The Women’s Health Initiative (WHI) demonstrated that adverse effects with hormone therapy were prevalent in women who were postmenopausal (over age 60). This is not the age group that presents with new onset menopausal symptoms.
When Can Estrogen Be Used?
Estrogen use in menopause is typically only safe when the uterus has been removed. It is known that estrogen therapy alone, with the uterus in place, will increase the risk of uterine cancer dramatically. Progesterone, the anti-estrogen, can help to avoid the development of uterine cancer, but typically cannot be used with estrogen in menopause since it increases various risks. These risks have been studied extensively in the Women’s Health Initiative (WHI) study, and are discussed below. References have been provided on WHI as well as other studies listed.
Hormone Replacement Therapy Risks and Complications
Though there are many benefits, there are also risks of hormone replacement therapy, most notably discovered through a large multicenter study organized by the Women’s Health Initiative (WHI). The risks of HRT include:
- Heart Disease: Heart disease is a risk of combination HRT, but has no known effect for ET
- Gallbladder/gallstone problems: Increased with both combination HRT and ET only
- Blood clots and stroke: Increased with HRT except with alternative applications of estrogen directly on the skin which may still reduce the risk of blood clots and stroke
- Endometrial cancer: This risk applies to women who still have their uterus and are taking estrogen therapy without progesterone
- Breast cancer: There is no known effect with ET, but there is an increased risk with combination HRT
- Dementia: There is a possible risk in women who have been in menopause for 10 years or longer
Possible Risk of HRT for Postmenopausal Women
* Extremely low incidence
There have been a number of very large, well-designed studies that examined the risks of both types of HRT. Much of the confusion regarding HRT stems from misinterpretation of the WHI.
- The WHI study was a large study of healthy postmenopausal women ranging in age from 55 to 79, with an average age of 61. It included over 160,000 women and was the largest and most comprehensive study done on this subject. It was designed specifically to assess the role of HRT for prevention of coronary heart disease (heart attacks) in women but also looked at other outcomes. There were two arms of this study3:
- Women with a uterus were randomly assigned to take either combination HRT or a placebo
- Women who had undergone a hysterectomy were randomly assigned to take either estrogen-only HRT or a placebo
As summarized below, patients who had their uterus removed can use ET safely with no increased risks of breast cancer, heart disease, colorectal cancer, and decreased fracture risk. There was an extremely low incidence for these patients of stroke and blood clots.
Patients who did not have a hysterectomy using combination estrogen and progesterone therapy had increased risks of breast cancer and heart disease, with decreased incidence of colorectal cancer and fractures. There was an increased risk of stroke and blood clots in this group that was somewhat higher than the ET group.
The WHI study shows that patients can use ET safely after menopause if the uterus is removed, with significant benefits regarding relief of menopausal symptoms and decreased fracture risk, with no increased risk of breast cancer or heart disease.
For women who have had or are considering getting a total hysterectomy, ET has shown to be beneficial, effective, and a safe choice for the short- and long-term relief of menopausal symptoms with fewer health risks than the combined estrogen/progesterone therapy.
Which HRT is Right for Me?
For patients who have had a hysterectomy and are menopausal, the use of ET is safe and beneficial until the age of 60.
The CIGC Difference
Whether a woman enters menopause naturally or surgically, at The Center for Innovative GYN Care® (CIGC®), our GYN surgical specialists have the experience to provide women with tailored hormone replacement therapy when appropriate and understand that each woman experiences menopause differently.
Part of the role of the surgeons at CIGC is to thoroughly evaluate each patient’s unique condition and provide insight to the right approach for therapy. While this may be a form of hormone replacement therapy, it may instead be a series of lifestyle adjustments to cope with the body’s changes.
CIGC surgeons specialize in minimally invasive GYN care. While focused primarily on surgery, additional treatments that support GYN health are critically important to overall patient well-being. Patients who require nonsurgical treatments are offered the best possible medical solutions.
CIGC surgeons are laparoscopic surgical specialists who have dedicated their careers to the performance of minimally invasive GYN care. Additionally, our commitment to surgery means that we have worked on a higher volume of cases, more difficult cases, and use advanced techniques and procedures learned during extensive training. We strive to complete even the most complex surgeries with low complication rates.
We know that our patients are particular when choosing their surgeons, and we think doing extensive research before choosing is important. When you are exploring your hormone replacement therapy options, get to know our surgical specialists and see why they are the best in the industry.
Hormone Replacement Therapy FAQs
The ovaries are responsible for the production of the female hormones: estrogen and progesterone. Along with the adrenal glands, they also produce testosterone. These hormones are released by the ovaries and circulate throughout the entire body. Many organs within the body have receptors for these hormones, such as the breast, uterine lining, vagina, bone, and blood vessels. These hormones are mainly responsible for reproduction, but also have a role in many other functions of the body, such as maintenance of bone and cardiovascular health, and in the regulation of body fluid. As a consequence of the hormonal changes associated with menopause, a woman’s risk for osteoporosis, heart disease, and vaginal dryness increases significantly after menopause.
Estrogen has a role in many systems within the body. Estrogen maintains vaginal lubrication and elasticity as well as skin collagen. It also stimulates breast tissue and the growth of the uterine lining, while helping to minimize the loss of calcium from the bones. After menopause, estrogen declines to very low levels.
Progesterone balances the effects of estrogen on the uterine lining, helps to prepare it for pregnancy, and helps to prevent potential cancer within the uterus caused by too much estrogen. Production of progesterone stops after menopause.
Testosterone contributes to sex drive and may build and maintain muscle mass. Testosterone levels peak in a woman’s 20s and gradually decline over time.
There are two types of hormone replacement therapy: estrogen-only (ET) or combination estrogen/progesterone therapy (EPT).
- ET is the safer form of HRT but should only be taken by women who have had a hysterectomy. Estrogen causes the lining of the uterus to thicken, so if a woman with a uterus takes estrogen-only HRT, the endometrium will thicken without the balancing effects of progesterone. This increases the risk for endometrial cancer.
- EPT must be used by women who still have a uterus. This is necessary in order to balance the effect of estrogen on the uterine lining and prevent overgrowth and the potential cancer within the uterus.
Trying to understand the role of hormone replacement therapy during menopause can be confusing. Conflicting information from the healthcare industry and media can result in unnecessary suffering. Whether a woman enters menopause naturally or surgically, at CIGC, our GYN surgical specialists have the experience to provide women with tailored hormone replacement therapy when appropriate and understand that each woman experiences menopause differently.
Natural menopause occurs when the ovaries no longer produce estrogen and progesterone and stop releasing eggs. It is diagnosed in hindsight, one year after a woman’s last period.
Surgical menopause occurs after both ovaries are removed. The average age of menopause in the United States is 51 years.
Perimenopause is the transitional period when a woman’s hormone production is declining. It begins, on average, four years before the final period. Hormonal fluctuations during this time can cause a variety of symptoms.
Common symptoms of menopause include:
- Irregular periods
- Hot flashes
- Sleep disturbances
- Mood swings
- Vaginal dryness
- Pain with sex/change in sex drive
- Joint aches
- Breast pain
Symptoms of menopause treated by HRT1,2:
- Reduction in the severity and frequency of hot flashes
- Improvement of moodiness and sleep problems
- Improvement of anxiety and depression
- Prevention of loss of bone density and osteoporosis
- Prevention of vaginal atrophy, dryness, and irritation
- Maintenance of skin collagen, which helps skin elasticity
Part of the role of the surgeons at CIGC is to thoroughly evaluate each patient’s unique condition and provide insight to the right approach for therapy. While this may be a form of hormone replacement therapy, it may instead be a series of lifestyle adjustments to cope with your body’s changes.
Lifestyle modifications have been shown to be effective for women with mild symptoms:
- Dressing in layers
- Sleeping with a fan nearby
- Using a vaginal lubricant
Antidepressants have been shown to help with hot flashes and mood changes and are good options for women who are unable to take estrogen:
- Brisdelle (Paroxetine) was recently approved in 2013 by the FDA as the first non-hormonal treatment for hot flashes associated with menopause
- Women on Tamoxifen should not take it, since it may decrease the effectiveness of Tamoxifen when taken together
- Venlafaxine (Effexor), Citalopram (Celexa), and Escitalopram (Lexapro) have all been shown to be effective in controlling hot flashes
- Fluoxetine (Prozac) is also helpful but less effective than Venlafaxine, Citalopram, and Escitalopram
- Sertraline (Zoloft) is not helpful
- Phytoestrogens: There is an enormous market for phytoestrogens, which are plant-derived from sources such as soybean and red clover, and although they are readily available, there is no good medical evidence that they actually work beyond a placebo effect
- Black Cohosh: Clinical studies have not shown black cohosh to be more effective than a placebo
Gabapentin (Neurontin) is a medication used to treat seizures and nerve pain. It has also been shown to be effective in treating hot flashes when taken once daily at bedtime.
Ready for a Consultation
If you’re considering hormone replacement therapy, our specialists are ready to provide an evaluation of your symptoms and conditions and recommend an appropriate solution.
Related Blog Posts
1 ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol. 2014 Jan;123(1):202-16
2 Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015 Sep;44(3):497-515
3 Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013 Oct 2;310(13):1353-68